Itovebi won US Food and Drug Administration (FDA) approval in this breast cancer indication based on INAVO120’s data late ...

Baseline tumor-infiltrating lymphocytes and positive nodes can help identify women with TMBC at high risk for relapse despite ...

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in ...

The results emphasize the importance of PARP inhibitors in BRCA-mutated breast cancer, particularly in triple-negative breast ...

The Itovebi, Ibrance, and fulvestrant combination demonstrated improved survival outcomes versus placebo in a Phase III trial.

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

Pfizer enters exclusive global, ex-China licensing pact with 3SBio for development, manufacturing & commercialization of SSGJ-707: New York Tuesday, May 20, 2025, 14:30 Hrs [IST] ...

Eleven-year follow-up data continue to show the invasive disease-free survival benefit for node-positive patients seen in previous analyses.